Table: Taisho Pharmaceutical HD -2022/23 group results
May 11 (Reuters)-
Taisho Pharmaceutical Holdings Co Ltd
CONSOLIDATED FINANCIAL HIGHLIGHTS
(in billions of yen unless specified)
Year ended Year ended Year to NEXT
Mar 31, 2023 Mar 31, 2022 Mar 31, 2024 YEAR
LATEST YEAR-AGO COMPANY COMPANY
RESULTS RESULTS FORECAST H1 FORECAST
Sales 301.38 268.20 314.50
(+12.4 pct) (-4.9 pct) (+4.4 pct)
Operating 23.02 10.74 18.50
(+114.3 pct) (-46.2 pct) (-19.6 pct)
Recurring 30.44 18.41 22.00
(+65.3 pct) (-29.0 pct) (-27.7 pct)
Net
Net 19.00 13.12 13.00
(+44.8 pct) (-1.5 pct) (-31.6 pct)
EPS 231.73 yen 161.12 yen 158.58 yen
EPS Diluted 231.43 yen 160.93 yen
Ann Div 100.00 yen 100.00 yen 100.00 yen
-Q2 Div 50.00 yen 50.00 yen 50.00 yen
-Q4 Div 50.00 yen 50.00 yen 50.00 yen
NOTE - Taisho Pharmaceutical Holdings Co Ltd.
*Second Net profit row denotes profit attributable to owners ofthe parent
To see Company Overview page, click reuters://REALTIME/verb=CompanyData/ric=4581.T
Recent news on Taisho Pharmaceutical Holdings Co
See all newsBrief: Curi RMB Capital, Kaname Capital To Request Tokyo Court To Revise Taisho Pharmaceutical's Squeeze Out Price If Taisho Disagrees With Their Demand - Nikkei
Brief: Curi RMB Capital, Kaname Capital To Request Tokyo Court To Revise Taisho Pharmaceutical's Tender Offer Price If Taisho Disagrees Their Demand - Nikkei
Activist fund Oasis says it may take legal action over Taisho's management buyout
Brief: Curi RMB Capital Opposes Taisho Pharmaceutical HD's Management Buyout
To Retire Treasury Shares Worth 3.65% Of Outstanding Stock On April 10